Yumiko Tani

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
There are limited data on the safety and efficacy of switching to secukinumab from cyclosporine A (CyA) in patients with psoriasis. The purpose of the present study was to assess the efficacy and safety of secukinumab for 16 weeks after direct switching from CyA in patients with moderate-to-severe psoriasis. In this multicenter, open-label, phase IV study,(More)
  • 1